Literature DB >> 26475307

Of standard of reference and accuracy: the problem of truth in imaging.

Stefano Fanti1, Elisabetta Lalumera2.   

Abstract

Mesh：

Year:  2016        PMID： 26475307     DOI： 10.1007/s00259-015-3207-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  1 in total

Review 1.  PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.

Authors:  Stefano Fanti; Silvia Minozzi; Paolo Castellucci; Sara Balduzzi; Ken Herrmann; Bernd Joachim Krause; Wim Oyen; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-09       Impact factor: 9.236
  1 in total
  3 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml.

Authors:  Giampiero Giovacchini; Priscilla Guglielmo; Paola Mapelli; Elena Incerti; Ana Maria Samanes Gajate; Elisabetta Giovannini; Mattia Riondato; Alberto Briganti; Luigi Gianolli; Andrea Ciarmiello; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-10       Impact factor: 9.236

3.  Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.

Authors:  Lino M Sawicki; Julian Kirchner; Carolin Buddensieck; Christina Antke; Tim Ullrich; Lars Schimmöller; Johannes Boos; Christoph Schleich; Benedikt M Schaarschmidt; Christian Buchbender; Philipp Heusch; Robert Rabenalt; Peter Albers; Gerald Antoch; Hans-Wilhelm Müller; Hubertus Hautzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-16       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.